Boston Scientific (BSX) Liabilities and Shareholders Equity (2009 - 2026)

Boston Scientific has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $45.2 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 8.8% year-over-year to $45.2 billion; the TTM figure through Jun 2026 stood at $175.9 billion (up 10.54% YoY), while the FY2025 annual figure was $43.7 billion, up 10.86% from the prior year.
• Liabilities and Shareholders Equity came in at $45.2 billion for Q2 2026 at Boston Scientific, up from $44.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $45.2 billion in Q2 2026 to a low of $31.9 billion in Q3 2022.
• Average Liabilities and Shareholders Equity over 5 years is $37.4 billion, with a median of $36.9 billion recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity climbed 0.22% in 2022 and increased 12.16% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $32.5 billion in 2022, then rose by 8.21% to $35.1 billion in 2023, then climbed by 12.12% to $39.4 billion in 2024, then climbed by 10.86% to $43.7 billion in 2025, then gained by 3.53% to $45.2 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $45.2 billion in Q2 2026, $44.4 billion in Q1 2026, and $43.7 billion in Q4 2025.